At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PF-07295324 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, VEHICLE-CONTROLLED, FIRST-IN-HUMAN, MULTIPLE-DOSE STUDY, TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS, OF TOPICALLY ADMINISTERED PF-07295324 AND PF-07259955, IN HEALTHY ADULT PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating PF-07295324 and PF-07259955 for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to evaluate the safety, (local and systemic) tolerability, and pharmacokinetics following multiple doses of topically applied, maximum feasible formulations of PF-07295324 (0.12% w/w) or PF-07259955 (2% w/w), on approximately 20% body surface area (BSA), in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartFeb 2022
Primary CompletionAug 2022
TodayJul 2026
First PostedJan 25, 2022
Enrollment StartFeb 9, 2022
Primary CompletionAug 12, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.4 years ago
Interventions
PF-07295324drug
Ointment
PF-07259955drug
Cream